17, 2024 -- The FDA last week approved Nemluvio for treating moderate to severe atopic dermatitis ... before starting treatment. Also, patients must notify their doctor about all medications ...

"With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there is now a therapy that offers the potential for powerful skin clearance with no ...

The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic ...

A study finding an association between dupilumab treatment for atopic dermatitis and a risk for cutaneous T-cell lymphoma topped the list. Content involving many other dermatitis treatments followed.

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...

The first patient was a 40-year-old atopic woman who presented with ... The patient's dermatitis resolved after treatment with topical corticosteroid ointment and discontinuation of retapamulin ...

Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ...

2,9-11 “As just one example of our innovative, science-based pipeline, Nemluvio is an important and effective new treatment option for patients with atopic dermatitis, where unmet needs remain.